– USA, CA – Teon Therapeutics, a clinical-stage biopharmaceutical company today announced the appointment of Serge Messerlian to its board of directors as CEO, assuming the role from co-founder, acting CEO, and CSO, Dr. Lina Yao who remains as CSO and a Board member.
About Serge Messerlian
Mr. Messerlian has an impressive track record of success, leading organizations in complex, highly competitive US and global markets with experience across multiple scientific disciplines, therapeutic areas, stages of drug development, and commercialization.
Mr. Messerlian brings to the role significant experience in the industry, across a range of roles and therapeutic areas including hematology, oncology, immunology, and rare diseases. He joins Teon from Janssen Oncology US, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, where he served as President and set the strategic direction for the organization and its key brands across hematology and solid tumors including DARZALEX, IMBRUVICA, ERLEADA, RYBREVANT, and platforms including cell therapies and bi-specifics. Previously he served in executive leadership roles as President of Actelion; Vice President, Global Portfolio Lead – Biosimilars at Baxalta; and Vice President, Global Portfolio Lead – Hematology at Baxter International.
“Throughout my career, I have been committed to improving the lives of people impacted by serious diseases like cancer. Supported by the pioneering groundwork done by our founders, I am confident in the future opportunities of Teon’s proprietary scientific approach and the passion and expertise of the team,” said Serge Messerlian. “Although GPCRs are the most intensively studied targets in many disease areas, their potential benefits for oncology are just beginning to be explored. Teon’s portfolio of small molecule candidates includes adenosine pathway inhibitors, as well as an oral immune checkpoint inhibitor that leverages novel GPCR biology and has us uniquely poised to bring more effective, first- or best-in-class oncology therapies to patients. I look forward to working with Lina and our remarkable scientific team, the board, and investors as we build the reputation and value of Teon.”
He holds a Bachelor of Science degree in Physiology and Biotechnology and a Master of Science degree in Human Genetics, both from McGill University and an MBA from the University of Toronto.
About Teon Therapeutics
Teon Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of cancer patients by developing a focused portfolio of oral, GPCR targeted small molecules that inhibit immunosuppressive and cancer-promoting signaling pathways in difficult-to-treat cancers. Teon’s rich pipeline includes adenosine pathway inhibitors as well as a small molecule immune checkpoint inhibitor. Teon initiated a Phase1/2 trial with its lead program, TT-702, an A2B receptor-specific antagonist, in 2021. The highly accomplished scientific leadership team are experts in adenosine and GPCR therapeutic design and development and were primary inventors of Lexiscan, the only FDA-approved selective adenosine therapeutic. Teon completed its $30M Series A financing round in February 2021.
For more information: https://teontherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.